Find insight on Fisher & Paykel Healthcare, Hims & Hers, GSK and more in the latest Market Talks covering health care.

Pharmaceutical companies breathed a sigh of relief on Wednesday, but the tariff reprieve could prove fleeting.

In a statement, Nxera CEO Chris Cargill said Kaneko’s appointment will help the company “maximize our commercial activities ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

FTSE 100 p harma giants GSK and Astrazeneca may have escaped the worst of US President Donald Trump’s tariffs, according to a ...

Stocks were down amid investor nervousness as to how countries would retaliate to Trump's tariffs, with fears over how an ...

On The Readout LOUD podcast, STAT reporters talk about new FDA commissioner Marty Makary's first week amid a swirl of layoffs ...

The broad STOXX 600 dropped to its lowest in two months and was last down 1.2%, but U.S. index futures fell more, around 3%, ...

Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients ...

An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any metastases with durvalumab vs placebo.

London stocks closed sharply lower on Thursday as global markets reacted negatively to US president Donald Trump’s ...

Pharma stocks rise as Trump exempts pharmaceuticals from reciprocal tariffs. Indian, UK, and Japanese drugmakers gain.